Halozyme Therapeutics and Catalyst Pharmaceuticals are notching double-digit increases in revenue and EPS. With little debt on their balance sheets, these companies can consider acquisitions. Neither stock looks overpriced, with valuations below the sector average. 10 stocks we like better than Halozyme Therapeutics › The biotech sector returned to health in 2025 after years of […]
Traveling ,Gardening & Finance
Traveling ,Gardening & Finance
